December 7, 2020

TissueTech Appoints Denise Spencer Vice President of Human Resources

Change champion will focus on aligning associates with organization’s mission, vision, and values in accordance with strategic business objectives

Miami, FL – December 7, 2020 – TissueTech, Inc., a pioneer in the clinical application of cryopreserved amniotic membrane and umbilical cord birth tissue allografts, announced today that Denise Spencer, MBA and Senior Professional in Human Resources International (SPHRi), has joined the organization in the capacity of Vice President, Human Resources. In this role, Denise will provide transformational leadership and direction to attract, retain, motivate, and reward a high-performance workforce for TissueTech and its subsidiaries Amniox and BioTissue.

TissueTech holds a long-standing commitment to diversity and inclusion, a fundamental area of expertise for Denise. In April 2014, the Greater Miami Chamber of Commerce recognized BioTissue’s exemplary business performance and contributions to the community as a minority-owned company by awarding it with a 2014 Top Minority Business Award.

“I am extremely pleased to welcome Denise to TissueTech’s senior leadership team. She is extremely well-versed in building high-performance teams throughout diverse and multi-cultural organizations such as ours,” said TissueTech co-founder Amy Tseng, President, and CEO. “She will be responsible for leading our human resources initiatives that support our strategic business plans and is well qualified with a solid reputation for building high-growth, culturally diverse teams.”

Denise received her undergraduate degree in Business and Hospitality Management from the University of Maine and is Lean Six-Sigma certified. She holds a Masters, Business Administration, Global Management from the University of Phoenix. Before joining TissueTech, Denise served as Vice President, Human Resources North America at GraceKennedy Foods, USA, and Vice President, Human Capital at AAR Corporation.

“I am eager to tap into the insight and experience of TissueTech employees as we look to build the company to achieve high levels of growth over the coming years,” Spence said. “I’m excited to be a part of such an innovative company and to help bring on and develop the talent to take it to the next level.

About TissueTech, Inc.

TissueTech, Inc., the parent company of Amniox Medical, Inc. and BioTissue, Inc., is a scientific and market leader in the field of regenerative medicine. TissueTech manufactures a broad range of ocular, surgical, wound care, and soft tissue products that are marketed under these subsidiaries. Since the company’s inception, clinicians have performed more than 500,000 human implants of the company’s products and published more than 360 peer-reviewed studies supporting its platform technology. TissueTech is committed to an unwavering culture of integrity that places our patients’ safety and clinical outcomes above all else. Learn more at

Related Content